Drugs / rDEN2/4 Δ30(ME)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01073306 | Feb → Jun 2010 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN2/4 Δ30(ME) | “A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects” NCT01073306 ↗ |
| Modality | Vaccine | “a vaccine developed to prevent infection with dengue virus type 2” NCT01073306 ↗ |
| Route | Subcutaneous | “Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)” NCT01073306 ↗ |